

Key abstracts accepted by AAD include:

Molecule/disease state	Abstract title	Abstract number/ presentation details
Rhapsido® (remibrutinib)		
CSU	Early symptom improvement with remibrutinib in chronic spontaneous urticaria: Daily Itch Severity Scores and Hives Severity Scores from phase 3 REMIX-1/-2 studies	Abstract #71668 e-Poster & Oral Presentation March 27, 3:15 pm MT
	Design of the REASSERT Study: A prospective, multi-country, noninterventional effectiveness and safety study evaluating remibrutinib in patients worldwide with chronic spontaneous urticaria (CSU)	Abstract #72973 e-Poster March 27
Burden of disease		
	Urticaria Voices: Treatment patterns and disease control in patients with self-reported chronic inducible urticaria	Abstract #75145 e-Poster March 27
Cosentyx® (secukinumab)		
HS	Flare prevention and safety of secukinumab vs bimekizumab in hidradenitis suppurativa: A matched adjusted indirect comparison analysis of Phase 3 trials	Abstract #76852 e-Poster & Oral Presentation Mar 27, 1:45 pm MT
	Designing a secukinumab dosing regimen in adolescents with moderate to severe hidradenitis suppurativa using model-informed drug development	Abstract #74494 e-Poster & Oral Presentation March 28, 2:00 pm MT
	Four-year efficacy of continuous secukinumab in SUNSHINE/SUNRISE core and extension trials on hidradenitis suppurativa (HS) lesions	Abstract #75099 e-Poster March 27
Psoriatic arthritis	Effectiveness of Secukinumab in Preventing Psoriatic Arthritis in Patients With Moderate to Severe Psoriasis	Abstract #73859 e-Poster & Oral Presentation March 28, 11:45 am MT
	Impact of Disease Duration on the Treatment Effect of Secukinumab in the Prevention of Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis: A 5-year Pooled Analysis of the ERASURE, FIXTURE and SCULPTURE Studies	Abstract #74500 e-Poster & Oral Presentation March 28, 2:05 pm MT